MedPath

The Characteristics of Blood Glucose Profile and the Changes of Hormones in PPDM-C Population

Not yet recruiting
Conditions
Chronic Pancreatitis
Diabetes
Registration Number
NCT06826729
Lead Sponsor
Shanghai Changzheng Hospital
Brief Summary

The purpose of this study was to explore the characteristics of blood glucose spectrum, changes of endocrine/exocrine pancreatic function and the correlation between them in patients with PPDM-C.

Detailed Description

The benefits of this study to participants include:

1. It will help to make early diagnosis or risk screening for the potential related risks and concomitant diseases of the disease;

2. Provide necessary suggestions for the treatment and intervention of the disease, or provide useful information for the related research of the disease.

3. We will provide Abbott version h dynamic glucose meter and assessment of internal and external secretion function. The researcher will provide professional endocrine related lifestyle and drug guidance for the subjects according to their CGMS data.

The risks that this study may bring to participants are:

There may be some very small risks in specimen collection, including transient pain, local cyanosis, etc. a few people will have mild dizziness or extremely rare needle infection.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
2000
Inclusion Criteria
  • Male or female Chinese subjects;

    • Was ≥ 18 years old when signing the informed consent;

      • Patients with complete diagnosis of chronic pancreatitis; ④ Those who voluntarily signed informed consent; ⑤ Those who complete serum samples in multiple centers and put them into storage.
Exclusion Criteria
  • Patients with impaired glucose tolerance but undiagnosed diabetes;

    • Patients with T1DM related autoimmune markers or other types of DM;

      • Patients with autoimmune pancreatitis, recurrent acute pancreatitis or acute onset of chronic pancreatitis;

        • Patients who underwent pancreatic surgery or related invasive procedures during treatment;

          • Previous or current malignant tumor; ⑥ Pregnancy or lactation; ⑦ Suffering from severe heart, liver or kidney dysfunction or malignant disease; ⑧ Failure to sign informed consent for cognitive impairment or other reasons.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Blood glucose profile characteristics of patients with PPDM-CFrom February 2025 to December 2025
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath